{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:26:49Z","timestamp":1768271209635,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K08505"],"award-info":[{"award-number":["23K08505"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.biopha.2025.118099","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T21:04:34Z","timestamp":1745874274000},"page":"118099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunotherapy using allogenic NK cells downregulates mitochondrial-related genes and inhibits the OXPHOS system of malignant meningioma"],"prefix":"10.1016","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-838X","authenticated-orcid":false,"given":"Ryosuke","family":"Maeoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0307-3657","authenticated-orcid":false,"given":"Ryosuke","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4286-9356","authenticated-orcid":false,"given":"Tsutomu","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5559-8519","authenticated-orcid":false,"given":"Yuki","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Ouji-Sageshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9974-3538","authenticated-orcid":false,"given":"Takayuki","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5438-6098","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"ement_6","key":"10.1016\/j.biopha.2025.118099_bib1","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.biopha.2025.118099_bib2","doi-asserted-by":"crossref","unstructured":"D.N. Louis, A. Perry, G. Reifenberger, A. von Deimling, D. Figarella-Branger, W.K. Cavenee, H. Ohgaki, O.D. Wiestler, P. Kleihues, D.W. Ellison, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol 131(6) (2016) 803-20.","DOI":"10.1007\/s00401-016-1545-1"},{"issue":"_5","key":"10.1016\/j.biopha.2025.118099_bib3","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.biopha.2025.118099_bib4","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2217\/fon-2018-0006","article-title":"An overview of meningiomas","volume":"14","author":"Buerki","year":"2018","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118099_bib5","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","article-title":"Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas","volume":"13","author":"Brastianos","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118099_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70514-z","article-title":"Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression","volume":"10","author":"Karimi","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.118099_bib7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/jnen\/nlaa152","article-title":"Spatially resolved and quantitative analysis of the immunological landscape in human meningiomas","volume":"80","author":"Yeung","year":"2021","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118099_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer-natural killer cell immunity cycle","volume":"20","author":"Huntington","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118099_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.21147\/j.issn.1000-9604.2018.02.02","article-title":"Tumor immunotherapy: new aspects of natural killer cells","volume":"30","author":"Li","year":"2018","journal-title":"Chin. J. Cancer Res"},{"issue":"18","key":"10.1016\/j.biopha.2025.118099_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189975","article-title":"Ex vivo expanded and activated natural killer cells prolong the overall survival of mice with glioblastoma-like cell-derived tumors","volume":"22","author":"Shida","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118099_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212455","article-title":"Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro","volume":"14","author":"Tanaka","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118099_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.reth.2022.07.001","article-title":"Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors","volume":"21","author":"Nakazawa","year":"2022","journal-title":"Regen. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.118099_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040998","article-title":"Effect of CRISPR\/Cas9-mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in vitro human glioblastoma cell growth","volume":"9","author":"Nakazawa","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118099_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11060-016-2186-x","article-title":"N. H, Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with \u03b3\u03b4T cells in human glioblastoma in vitro and in vivo","volume":"129","author":"Nakazawa","year":"2016","journal-title":"J. Neuro-Oncol."},{"issue":"20","key":"10.1016\/j.biopha.2025.118099_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130688","article-title":"Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK","volume":"4","author":"Giles","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.biopha.2025.118099_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10616-014-9692-5","article-title":"Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA)","volume":"67","author":"Roshan Moniri","year":"2015","journal-title":"Cytotechnology"},{"key":"10.1016\/j.biopha.2025.118099_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.aca.2012.12.047","article-title":"Cytotoxicity assessment based on the AUC50 using multi-concentration time-dependent cellular response curves","volume":"764","author":"Pan","year":"2013","journal-title":"Anal. Chim. Acta"},{"issue":"1","key":"10.1016\/j.biopha.2025.118099_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13046-023-02770-6","article-title":"CIS deletion by CRISPR\/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma","volume":"42","author":"Nakazawa","year":"2023","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.biopha.2025.118099_bib19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"issue":"3","key":"10.1016\/j.biopha.2025.118099_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032111","article-title":"Natural killer cell-based immunotherapy against glioblastoma","volume":"24","author":"Morimoto","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118099_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073489","article-title":"CRISPR-Cas9-mediated TIM3 knockout in human natural killer cells enhances growth inhibitory effects on human glioma cells","volume":"22","author":"Morimoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118099_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00190","article-title":"Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 Blockade","author":"Dunn","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118099_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/cas.15221","article-title":"Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma","volume":"113","author":"Nakano","year":"2022","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118099_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","article-title":"Advances in meningioma genetics: novel therapeutic opportunities","volume":"14","author":"Preusser","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118099_bib25","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.cell.2006.06.010","article-title":"Mitochondria: dynamic organelles in disease, aging, and development","volume":"125","author":"Chan","year":"2006","journal-title":"Cell"},{"issue":"2 Pt A","key":"10.1016\/j.biopha.2025.118099_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2014.04.001","article-title":"The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism","volume":"356","author":"Lu","year":"2015","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.biopha.2025.118099_bib27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/bies.20463","article-title":"The role of mitochondrial respiration in physiological and evolutionary adaptation","volume":"28","author":"Das","year":"2006","journal-title":"Bioessays"},{"issue":"5","key":"10.1016\/j.biopha.2025.118099_bib28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11596-023-2771-0","article-title":"Roles of MT-ND1 in Cancer","volume":"43","author":"Xu","year":"2023","journal-title":"Curr. Med. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118099_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28808","article-title":"Mitochondrial complex I subunit MT-ND1 mutations affect disease progression","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2025.118099_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mito.2020.02.001","article-title":"Mitochondrial-associated impairments of temozolomide on neural stem\/progenitor cells and hippocampal neurons","volume":"52","author":"Lomeli","year":"2020","journal-title":"Mitochondrion"},{"issue":"5","key":"10.1016\/j.biopha.2025.118099_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s10989-023-10558-7","article-title":"A review on mitochondrial derived peptide humanin and small humanin-like peptides and their therapeutic strategies","volume":"29","author":"Thamarai Kannan","year":"2023","journal-title":"Int. J. Pept. Res. Ther."},{"issue":"16","key":"10.1016\/j.biopha.2025.118099_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164061","article-title":"Mitochondrial peptide humanin facilitates chemoresistance in glioblastoma cells","volume":"15","author":"Pena Agudelo","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.biopha.2025.118099_bib33","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","article-title":"Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis","volume":"185","author":"Pan","year":"2022","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biopha.2025.118099_bib34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/joim.12470","article-title":"The immune system and cancer evasion strategies: therapeutic concepts","volume":"279","author":"Muenst","year":"2016","journal-title":"J. Intern Med"},{"key":"10.1016\/j.biopha.2025.118099_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting; from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118099_bib36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2025.118099_bib37","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ajpath.2012.07.033","article-title":"Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas","volume":"181","author":"Domingues","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118099_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-013-1265-5","article-title":"Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours","volume":"116","author":"Kmiecik","year":"2014","journal-title":"J. Neurooncol"},{"issue":"2","key":"10.1016\/j.biopha.2025.118099_bib39","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10143-021-01642-x","article-title":"The role of systemic inflammatory cells in meningiomas","volume":"45","author":"Haslund-Vinding","year":"2022","journal-title":"Neurosurg. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2025.118099_bib40","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1172\/JCI129338","article-title":"Killers 2.0: NK cell therapies at the forefront of cancer control","volume":"129","author":"Hodgins","year":"2019","journal-title":"J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.biopha.2025.118099_bib41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118099_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.592470","article-title":"Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in patients with meningiomas","volume":"10","author":"Kuranari","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2025.118099_bib43","doi-asserted-by":"crossref","first-page":"1077053","DOI":"10.3389\/fonc.2022.1077053","article-title":"Contribution of natural killer cells in innate immunity against colorectal cancer","volume":"12","author":"Ghazvinian","year":"2022","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118099_bib44","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1424673","article-title":"In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: a phase I clinical trial","volume":"7","author":"Adotevi","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2025.118099_bib45","article-title":"Blood brain barrier: a challenge for effectual therapy of brain tumors","author":"Bhowmik","year":"2015","journal-title":"Biomed. Res Int 2015"},{"issue":"1","key":"10.1016\/j.biopha.2025.118099_bib46","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/s41467-022-29945-7","article-title":"Mitofusin 1 and 2 regulation of mitochondrial DNA content is a critical determinant of glucose homeostasis","volume":"13","author":"Sidarala","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225002938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225002938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T19:56:50Z","timestamp":1759003010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225002938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":46,"alternative-id":["S0753332225002938"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118099","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy using allogenic NK cells downregulates mitochondrial-related genes and inhibits the OXPHOS system of malignant meningioma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118099"}}